Skip to main content

Table 3 Risk of tuberculosis in patients with rheumatoid arthritis according to treatment for latent tuberculosis infection

From: Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013–2018

  

Anti-TNF

 

All

ETA

INF

ADA

GOL

TOC

In patients without evidence of latent tuberculosis infection

 

(n = 3568)

(n = 655)

(n = 448)

(n = 920)

(n = 676)

(n = 869)

 Duration of follow-up (days), median (IQR)

553

(227–1050)

629

(253–1196)

583

(216–1161)

510

(216–925)

470

(203–958)

608

(271–1061)

 Person-years

6421.3

1295.9

844.4

1549.0

1113.1

1618.9

 Case of TB, n

34

4

10

9

6

5

 Rate/100,000 person-years (95% CI)

529.5

(370.9–727.9)

308.7

(95.8–717.0)

1184.2

(593.4–2077.9)

581.0

(279.2–1047.3)

539.0

(214.2–1092.2)

308.9

(110.7–663.8)

 Adjusted IRRa

 

1.00 (ref)

3.65

(1.14–11.7)

2.18

(0.66–7.14)

2.00

(0.56–7.16)

1.07

(0.29–4.04)

In patients who were treated for latent tuberculosis infection before biologic therapy

 

(n = 1168)

(n = 279)

(n = 113)

(n = 298)

(n = 182)

(n = 296)

 Duration of follow-up (days), median (IQR)

612

(248–1134)

680

(257–1315)

803

(271–1230)

506

(221–963)

549

(213–1144)

668

(304–1066)

 Person-years

2229.5

583.8

242.7

501.9

334.3

566.8

 Case of TB, n

14

3

3

3

0

5

 Rate/100,000 person-years

(95% CI)

627.9

(353.7–1016.6)

513.9

(127.8–1332.0)

1236.2

(307.4–3204.4)

597.7

(148.6–1549.4)

_

882.2

(316.3–1896.0)

 Adjusted IRR

 

1.00 (ref)

2.54

(0.50–12.96)

0.93

(0.18–4.70)

_

1.35

(0.32–5.80)

  1. TNF tumor necrosis factor, ETA etanercept, INF infliximab, ADA adalimumab, GOL golimumab, TOC tocilizumab, IQR interquartile range, TB tuberculosis, CI confidence interval, IRR incidence rate ratio
  2. aThe IRR was adjusted for age, sex, and entry year